Study S001719

Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00971659
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 48
Start: 2008-01
Primary completion: 2008-09
Lead sponsor: Profil Institut für Stoffwechselforschung GmbH
Conditions: Type 2 Diabetes
Interventions: DRUG:insulin glargine + exenatide + preexisting metformin; DRUG:insulin glargine + sitagliptin + preexisting metformin; DRUG:insulin glargine + preexisting metformin
Results posted: FALSE

Registered primary outcomes

the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast [after 4 weeks of treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027899	Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Arnolds S, Diabetes care	2010	Randomized trial	PMID 20357372 DOI	cites ClinicalTrials.gov:NCT00971659; registry reference DERIVED:20357372